Fifty-five neuroendocrine tumours and 6 adrenocortical tumours were examined immunohistochemically for the expression of neuron-specific enolase (NSE), chromogranin and synaptophysin. The results were compared with the staining patterns obtained with peanut lectin (PNA) using a streptavidin-biotin staining technique. In separate experiments, sections were preincubated with neuraminidase for the demonstration of masked PNA binding sites. Two of the 24 phaeochromocytomas, 1 of the 6 medullary carcinomas of the thyroid gland, 5 out of the 7 islet cell tumours of the pancreas and all 4 extra-adrenal paragangliomas were negative with PNA. When the sections were first incubated with neuraminidase all these tumours were positive with PNA. Six adrenocortical tumours and 7 neuroblastomas were examined and found to be negative with PNA with or without neuraminidase pre-treatment. Seven carcinoid tumours were examined and found to be positive with PNA only in tubular areas and negative in solid areas; pre-treatment with neuraminidase did not alter the staining pattern. Immunoreactivity for NSE was absent in only 1 of the neuroendocrine tumours. A higher proportion of neuroendocrine tumours was positive with anti-chromogranin than with anti-synaptophysin.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/BF01626349 | DOI Listing |
PLoS One
January 2025
Department of Clinical Medicine, Centre for Cancer Biomarkers CCBIO, University of Bergen, Bergen, Norway.
The prognosis for patients with melanoma loco-regional metastases is very heterogenous. Adjuvant PD-L1-inhibitors have improved clinical outcome for this patient group, but the prognostic impact of tumour PD-L1 expression and number of tumour infiltrating lymphocytes (TILs) is still largely unknown. Here, we investigated the impact on survival for CD3, CD8, FOXP3 and PD-L1 TIL counts and tumour PD-L1 expression in melanoma loco-regional metastases.
View Article and Find Full Text PDFJMIR Cancer
January 2025
Department of Medical Oncology, Antoni van Leeuwenhoek, Amsterdam, Netherlands.
Background: Patients with melanoma receiving immunotherapy with immune-checkpoint inhibitors often experience immune-related adverse events, cancer-related fatigue, and emotional distress, affecting health-related quality of life (HRQoL) and clinical outcome to immunotherapy. eHealth tools can aid patients with cancer in addressing issues, such as adverse events and psychosocial well-being, from various perspectives.
Objective: This study aimed to explore the effect of the Cancer Patients Better Life Experience (CAPABLE) system, accessed through a mobile app, on HRQoL compared with a matched historical control group receiving standard care.
Nucl Med Mol Imaging
February 2025
Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul, 06351 Republic of Korea.
This guideline outlines the use of 3,4-dihydroxy-6-F-fluoro-L-phenylalanine positron emission tomography / computed tomography for the diagnosis and management of neuroendocrine tumors, brain tumors, and other tumorous conditions. It provides detailed recommendations on patient preparation, imaging procedures, and result interpretation. Based on international standards and adapted to local clinical practices, the guideline emphasizes safety, quality control, and the effective application of 3,4-dihydroxy-6-F-fluoro-L-phenylalanine positron emission tomography / computed tomography for various tumors such as insulinomas, pheochromocytomas, and medullary thyroid carcinoma.
View Article and Find Full Text PDFIndian J Endocrinol Metab
December 2024
Department of Nuclear Medicine, Christian Medical College, Vellore, Tamil Nadu, India.
Introduction: Functioning neuroendocrine tumors (NETs) that do not respond to standard therapies are commonly considered for Peptide Receptor Radionuclide Therapy (PRRT). The benefit of Lu-DOTATATE PRRT in patients with progressive metastatic NET was analyzed and survival in multi-organ involvement.
Methods: Forty-one patients with refractory, progressive, or advanced symptomatic NETs, with or without previous treatment modalities were studied.
J Exp Clin Cancer Res
January 2025
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Recent advances in oncology research have highlighted the promising synergy between low-dose radiation therapy (LDRT) and immunotherapies, with growing evidence highlighting the unique benefits of the combination. LDRT has emerged as a potent tool for stimulating the immune system, triggering systemic antitumor effects by remodeling the tumor microenvironment. Notably, LDRT demonstrates remarkable efficacy even in challenging metastatic sites such as the liver (uveal) and brain (cutaneous), particularly in advanced melanoma stages.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!